These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 26348216)
21. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data. Swanson MS; Sinha UK Oral Oncol; 2015 Jan; 51(1):12-5. PubMed ID: 25459157 [TBL] [Abstract][Full Text] [Related]
22. Cancer immunotherapy comes of age and looks for maturity. Finck A; Gill SI; June CH Nat Commun; 2020 Jul; 11(1):3325. PubMed ID: 32620755 [TBL] [Abstract][Full Text] [Related]
24. Seminal immunologic discoveries with direct clinical implications: The 2018 Nobel Prize in Physiology or Medicine honours discoveries in cancer immunotherapy. Ljunggren HG; Jonsson R; Höglund P Scand J Immunol; 2018 Dec; 88(6):e12731. PubMed ID: 30485497 [No Abstract] [Full Text] [Related]
25. Introduction: Cancer Immunology Special Issue-Immunotherapy. Kawakami Y Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100 [No Abstract] [Full Text] [Related]
26. Immune checkpoint blockade: a common denominator approach to cancer therapy. Topalian SL; Drake CG; Pardoll DM Cancer Cell; 2015 Apr; 27(4):450-61. PubMed ID: 25858804 [TBL] [Abstract][Full Text] [Related]
27. Update on the current revolution in cancer immunotherapy. Renrick AN; Dunbar ZT; Shanker A Immunotherapy; 2019 Jan; 11(1):15-20. PubMed ID: 30702010 [No Abstract] [Full Text] [Related]
28. [Immunotherapy of Bronchogenic Carcinoma and Its Perspectives]. Koubková L Klin Onkol; 2015; 28 Suppl 4():4S77-81. PubMed ID: 26647894 [TBL] [Abstract][Full Text] [Related]
29. Checkpoint inhibitors: outstanding efficacy but at what cost? Klastersky JA Curr Opin Oncol; 2016 Jul; 28(4):253. PubMed ID: 27163724 [No Abstract] [Full Text] [Related]
30. [Regulatory T cells in cancer immunotherapy]. Nishikawa H Rinsho Ketsueki; 2014 Oct; 55(10):2183-9. PubMed ID: 25297785 [No Abstract] [Full Text] [Related]
31. [What opportunities does Immuno-oncology indicate for overarching long-term survival?]. Bergmann L; Brugger W; Herr W; Mackensen A; Multhoff G Oncol Res Treat; 2015; 38 Suppl 3():6-11. PubMed ID: 25966812 [No Abstract] [Full Text] [Related]
32. Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop. Berraondo P; Ochoa MC; Rodriguez-Ruiz ME; Minute L; Lasarte JJ; Melero I Cancer Res; 2016 May; 76(10):2863-7. PubMed ID: 27308833 [TBL] [Abstract][Full Text] [Related]
34. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Allard B; Pommey S; Smyth MJ; Stagg J Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257 [TBL] [Abstract][Full Text] [Related]
35. The Era of Immune Checkpoint Therapy: From Cancer to Viral Infection-A Mini Comment on the 2018 Medicine Nobel Prize. Liu J; Pan W; Yang D Virol Sin; 2018 Dec; 33(6):467-471. PubMed ID: 30570713 [No Abstract] [Full Text] [Related]
36. Immunotherapy 2.0: Improving the Response to Checkpoint Inhibitors. Friedrich MJ JAMA; 2019 Jan; 321(2):131-133. PubMed ID: 30566194 [No Abstract] [Full Text] [Related]